HURA

+ Watchlist + Portfolio

TuHURA Biosciences, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.98
52-Week Range: $0.41 – $3.43
Market Cap: $121.72M
P/E (TTM): —
EPS (TTM): -0.54
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 6.68
PEG Ratio: —
Return on Equity: -161.39%
Return on Assets: -58.43%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.18
Debt/Equity: 0.50
Total Debt: $9.18M
Free Cash Flow: $-18.28M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $130.18M

HURA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.93M	$9.40M	$13.34M	$20.53M
Selling, General & Admin	$2.01M	$4.14M	$3.87M	$7.58M
Operating Expenses	$9.72M	$13.17M	$17.15M	$27.29M
Operating Income	-$9.72M	-$13.17M	-$17.15M	-$27.29M
EBITDA	-$8.99M	-$29.12M	-$17.43M	-$29.36M
Pretax Income	-$9.37M	-$29.32M	-$21.68M	-$30.05M
Net Income	-$9.37M	-$29.32M	-$21.68M	-$30.05M
Diluted EPS	-0.77	-2.47	-1.21	-0.63
Diluted Shares	12.18M	11.89M	18.66M	47.93M

HURA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$14.25M	$3.67M	$12.66M	$3.62M
Receivables	$101.42K	$334.44K	$437.40K	$500.00K
Current Assets	$14.74M	$4.16M	$19.61M	$4.62M
Total Assets	$15.20M	$4.36M	$19.97M	$27.35M
Current Liabilities	$2.87M	$3.60M	$5.33M	$5.92M
Long-Term Debt	—	$2.32M	—	—
Total Debt	$138.22K	$2.34M	$202.54K	$700.02K
Total Liabilities	$2.89M	$5.92M	$5.37M	$6.42M
Retained Earnings	-$59.16M	-$88.47M	-$111.12M	-$141.18M
Shareholders' Equity	$12.30M	-$1.56M	$14.59M	$20.93M
Working Capital	$11.87M	$562.42K	$14.28M	-$1.30M

HURA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$7.51M	-$11.95M	-$14.73M	-$27.63M
Capital Expenditure	-$36.28K	-$79.22K	-$57.91K	-$76.08K
Free Cash Flow	-$7.54M	-$12.03M	-$14.79M	-$27.71M
Depreciation & Amortisation	$373.09K	$177.38K	$116.71K	$71.27K
Stock-Based Compensation	$218.28K	$478.89K	$1.96M	$6.42M
Investing Cash Flow	-$36.28K	-$1.30M	-$6.05M	-$1.34M
Financing Cash Flow	$16.25M	$2.66M	$29.77M	$19.93M
Dividends Paid	—	—	$0.00	-$8.36K
Share Repurchases	$0.00	-$24.75K	$0.00	—
Net Change in Cash	$8.71M	-$10.59M	$8.99M	-$9.04M

HURA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$4.58M	$4.93M	$4.97M	$6.06M	$5.23M	$6.62M
Selling, General & Admin	$2.02M	$1.86M	$1.76M	-$1.56M	$2.30M	$2.14M
Operating Expenses	$6.35M	$6.47M	$6.59M	$4.38M	$7.53M	$8.76M
Operating Income	-$6.35M	-$6.47M	-$6.59M	-$4.38M	-$7.53M	-$8.76M
EBITDA	-$6.65M	-$9.51M	-$7.06M	-$6.13M	-$7.49M	-$8.73M
Pretax Income	-$6.66M	-$9.52M	-$7.10M	-$6.76M	-$7.54M	-$9.22M
Net Income	-$6.66M	-$9.52M	-$7.10M	-$6.76M	-$7.54M	-$9.22M
Diluted EPS	-0.15	-0.21	-0.14	—	-0.13	-0.14
Diluted Shares	43.40M	44.56M	50.67M	—	60.01M	63.96M

HURA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$6.22M	$8.51M	$2.70M	$3.62M	$6.30M	$995.98K
Receivables	$310.25K	$3.41M	$214.70K	$500.00K	$0.00	$0.00
Current Assets	$14.33M	$12.54M	$3.50M	$4.62M	$6.98M	$1.66M
Total Assets	$14.64M	$34.62M	$25.70M	$27.35M	$29.70M	$31.75M
Current Liabilities	$4.78M	$15.17M	$8.83M	$5.92M	$6.07M	$9.26M
Long-Term Debt	—	—	—	—	—	$3.60M
Total Debt	$164.59K	$558.97K	$577.73K	$700.02K	$456.93K	$9.18M
Total Liabilities	$4.78M	$15.17M	$8.92M	$6.42M	$6.51M	$13.25M
Retained Earnings	-$117.79M	-$127.32M	-$134.42M	-$141.18M	-$148.72M	-$157.95M
Shareholders' Equity	$9.86M	$19.45M	$16.78M	$20.93M	$23.19M	$18.50M
Working Capital	$9.54M	-$2.63M	-$5.33M	-$1.30M	$915.38K	-$7.60M
Net Debt	—	—	—	—	—	$7.78M

HURA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$4.74M	-$6.25M	-$11.09M	-$5.56M	-$4.41M	-$8.63M
Capital Expenditure	-$42.67K	-$5.56K	—	-$27.85K	-$48.85K	-$136.98K
Free Cash Flow	-$4.78M	-$6.25M	-$11.09M	-$5.58M	-$4.46M	-$8.77M
Depreciation & Amortisation	$14.06K	$13.37K	$21.29K	$22.54K	$23.47K	$28.10K
Stock-Based Compensation	$1.42M	$1.41M	$1.63M	$1.96M	$2.80M	$2.14M
Investing Cash Flow	-$1.15M	-$156.46K	$0.00	-$27.85K	-$48.85K	-$136.98K
Financing Cash Flow	-$547.88K	$8.70M	$5.27M	$6.51M	$7.14M	$3.47M
Dividends Paid	-$2.09K	-$2.09K	-$2.09K	-$2.09K	-$2.09K	-$2.09K
Net Change in Cash	-$6.44M	$2.29M	-$5.82M	$922.53K	$2.68M	-$5.30M

Market Snapshot

About

TuHURA Biosciences, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer. The company's pipeline includes multiple product candidates targeting various oncology indications, with a focus on small molecule inhibitors and novel mechanisms of action. TuHURA's lead programs include IMP-1734, an oral inhibitor being developed for solid tumors, and other candidates in preclinical and clinical development stages. The company utilizes a platform approach to drug discovery and development, focusing on precision medicine and biomarker-driven patient selection. TuHURA Biosciences was formerly known as Coronado Biosciences and rebranded to reflect its new strategic focus on oncology therapeutics. The company is headquartered in San Diego, California.